Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations
5.6.2017 13:30 | NASDAQ OMX
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Karen Koski as Head of Strategy and Investor Relations. The newly created position will report directly to Oxford Immunotec's Chief Executive Officer, Dr. Peter Wrighton-Smith. Ms. Koski will join the company on June 21, 2017.
"We are very excited to add Karen to the Oxford Immunotec team. She is not only extremely knowledgeable about the diagnostics and blood banking industries, but very familiar with our story and long-term strategy," said Dr. Wrighton-Smith. "Karen's professional experience and knowledge of our industry will be invaluable as we execute on our strategic growth plans and work to maximize shareholder value."
Ms. Koski joins the Company with a wealth of knowledge and experience in the diagnostics industry. Most recently, Ms. Koski served as a Director and Senior Equity Analyst at BTIG, LLC where she covered companies in the Medical Technology, Life Sciences, and Diagnostics sectors. Prior to joining BTIG, Ms. Koski worked as an Equity Research Associate at Lazard Capital Markets, where she focused on the Medical Technology sector. Earlier in her career, Ms. Koski served as a Medical Technologist at Brigham and Women's Hospital in Boston, Mass., where she specialized in clinical hematology, clinical microbiology, clinical chemistry, and blood banking. Ms. Koski holds a B.S. in Medical Technology from the University of Vermont.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock29.6.2017 00:47 | Pressmeddelande
WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38,750,000. The offering is expected to close on or about July 5th, 2017, subject to customary closing conditions. Citigroup and Jefferies are acting as the book-running managers for the offering, and JMP Securities is acting as lead manager for the offering. Minerva has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock, on the same terms and conditions. Minerva intends to use the net proceeds from the offering, together with its existing cash and investments, to fund part of th
Yandy.com Celebrates Baywatch Movie With Inspired-By Swim Collection28.6.2017 20:18 | Pressmeddelande
Yandy launches swim collection for domestic and international consumers PHOENIX, June 28, 2017 (GLOBE NEWSWIRE) -- Yandy.com, the leading online retailer of intimates, swimwear, and specialty apparel, announced today the top-performing swimsuits from its Baywatch ® swimwear collection. To celebrate the film's U.S. release - Yandy.com produced, marketed and sold three swimwear designs inspired by looks worn by the movie's female lifeguard characters. The new Baywatch movie follows devoted lifeguard Mitch Buchannon (Dwayne Johnson) as he butts heads with a brash new recruit (Zac Efron). Together, they uncover a local criminal plot that threatens the future of the Bay. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d8a5-c973-4449-be85-6289c481671c Yandy's release of the Baywatch-inspired collection in May demonstrated an immediate interest among domestic consumers. No
Nasdaq's Directors Desk® and Boardvantage® to Introduce Board Assessments and Compliance Questionnaires28.6.2017 16:05 | Pressmeddelande
A Unique Collaboration between Nasdaq Corporate Solutions and the Center for Board Excellence NEW YORK and GREENSBORO, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- Nasdaq Corporate Solutions, a business of Nasdaq, Inc. (Nasdaq:NDAQ), announced today a new partnership with The Center for Board Excellence (CBE), a provider of board assessments and compliance questionnaires. In the first phase of the partnership, Nasdaq Corporate Solutions will facilitate introductions for users of Directors Desk and Boardvantage - Nasdaq's board portal and meeting management solutions - to CBE's cloud-based corporate governance solutions including: board and committee assessments; director peer assessments; CEO and management evaluations; and directors' & officers' questionnaires. Later this year, the parties plan to offer an integrated workflow between Nasdaq's board portal solutions and CBE's EnGauge(TM) platform, making it even easier for users to elect to benefit fr
Datameer : Datameer Announces Industry-First Solution for Deploying AI to the Enterprise at Big Data Scale28.6.2017 15:00 | Pressmeddelande
New Datameer SmartAI democratizes data science within organizations by operationalizing deep learning models with enterprise scale and governance SAN FRANCISCO, June 28, 2017 (GLOBE NEWSWIRE) -- Furthering its mission to democratize data access within the enterprise, Datameer today unveiled SmartAI, an industry-first solution for operationalizing deep learning models directly within enterprise data lake environments securely and at scale. SmartAI finally allows enterprises to democratize data science, taking the deep learning work of data scientists from the lab to the business in production-ready scenarios that meet the big data security, governance and management standards IT requires. Now, business analysts can apply and execute trusted deep learning models against massive datasets from enterprise data lakes to drive better business outcomes. "With all the promise of data science and artificial intelligence, organizations have had difficulty delivering on its busi
Imperial Capital Hires Two Senior Sales Professionals Forming a Dedicated Convertible Institutional Sales Group28.6.2017 14:30 | Pressmeddelande
LOS ANGELES, June 28, 2017 (GLOBE NEWSWIRE) -- Imperial Capital Group, LLC ("Imperial Capital") announced today the hiring of James P. Kenney and Kevin Cadden, two senior institutional convertible sales professionals, forming a dedicated Convertible Sales Group, while adding to the franchise's continued credit sales & trading growth initiatives. The group will be responsible for expanding Imperial Capital's existing credit sales and trading business further into convertible products while working with a team of seasoned trading and research professionals to provide its institutional clients with valuable market color, trading ideas and excellent execution in both the fixed income and equity markets. "With the hiring of James and Kevin, we are able to provide our institutional clients with a team of veteran sales and trading professionals specializing in the convertible bond marketplace," said Tom Corcoran, President of Imperial Capital. "The team bri
AGF Management Limited Reports Strong Second Quarter 2017 Financial Results28.6.2017 14:00 | Pressmeddelande
30% growth in mutual fund gross sales compared to prior year quarter 50% of ranked AUM performed above median for the one-year period ended May 31, 2017, and 53% for the three-year period Achieved final close of InstarAGF Essential Infrastructure Fund (EIF) with $740 million in commitments Reported Diluted EPS of $0.16 compared to $0.12 in Q2 2016 TORONTO, June 28, 2017 (GLOBE NEWSWIRE) -- AGF Management Limited (AGF or the Company) today announced financial results for the second quarter ended May 31, 2017. Total assets under management (AUM) increased 8.0% to $36.4 billion compared to the same period in 2016, and up 3.7% compared to $35.1 billion as at February 28, 2017. AUM increased across all lines of business, including retail, private client, institutiona
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum